Affimed Provides Promising Data on AFM24 plus Atezolizumab Treatment
Saturday, 1 June 2024, 14:12
Affimed AFM24 Treatment Update
The latest update from Affimed reveals promising results for AFM24 plus Atezolizumab treatment in heavily pretreated NSCLC patients.
Durable Responses
The data shows durable responses in both EGFR wild-type and mutant cohorts, indicating potential efficacy in challenging cases.
This positive development underscores the promising impact of this combination therapy in NSCLC treatment.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.